Skip to main content
. 2020 Jul 23;10(20):9395–9406. doi: 10.7150/thno.48392

Figure 2.

Figure 2

Neither PD-L1 nor PD-1 expression on intratumoral immune cells influences LRC or PFS in HNSCC patients undergoing chemoradiation. LRC (A) and PFS (B) in HNSCC patients undergoing chemoradiation in dependence of the intratumoral immune cells' PD-L1 expression in pre-therapeutic tumor biopsies. LRC (C) and PFS (D) in HNSCC patients stratified by the expression levels of intratumoral PD-1. P values are derived from log-rank tests.